Low-dose ASA has long been an option for patients with AF

[Argirios Argiriou]

Low-dose ASA has long been an option for patients who have contraindications to or do not want to take anticoagulants.
In older studies, warfarin reduced the risk of stroke by about 65% and ASA by only about 20% compared to placebo.
More recent comparisons have shown a halving of the risk of stroke without significantly more bleeding with warfarin or apixaban compared with ASA. The risk-benefit ratio is thus considerably better for anticoagulants as stroke prophylaxis in AF (Atrial Fibrilation).

Translated with DeepL.com (free version)

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος